21 Jul
2016
In November 2015, FDA declared Caldolor® safe for intravenous ibuprofen injection in pediatric patients over six months of age. FDA’s approval came as a result of cumulative data submitted for review, derived from clinical trials performed on pediatric inpatients. During testing procedures, considerable temperature reduction was observed over complete duration of dosage, while less than two percent of total patients exhibited minor side effects, such as mild pain at the site of infusion, nausea, and vomiting. The world intravenous ibuprofen market witnesses the event in the light a novice opportunity segment for expansion of business.
Pain is indicative of tissue damage and raises the flag for immediate medical attention. Considering the patients under continuous monitoring, there is no requirement of any such indicators and must be eliminated to add comfort in healing process. Permitted class of pain killers are used quite frequently to serve the purpose. Ibuprofen belongs to this class of compounds, widely used by medical practitioners in their prescriptions.
Ibuprofen, or iso-butyl-propanoic-phenolic acid, is the generic name for a non-steroidal anti-inflammatory drug (NSAID). Intravenous (IV) ibuprofen has till date been generally used as short-term analgesic treatment for mild to moderate pain in adults, and complementary to opioids in moderate to severe pains. They are also known to control mild fevers, while its proportioned dosage helps reduce swelling in tissues. Its highly diluted solution is injected through a vein over a duration of 30 minutes. Increased water retention in host body is advised before and after administration, excluding individual case requirements.
IV ibuprofen injections can be administered to a patient with or without professional supervision. Under the absence of any medical supervision, low concentrate dosages, plus lesser frequency of shots, is maintained for intravenous ibuprofen. Random trials, conducted during several independent researches, have proved its effective application in acute and post-operative pain and fever management for inpatients at healthcare facilities.
Read more details about report at: https://www.alliedmarketresearch.com/intravenous-ibuprofen-market
Included in the WHO’s list of essential drugs, ibuprofen is one of the drug elements, which ensures completeness of basic healthcare provisions. A huge global population relies on this ‘popular’ drug because of the multiple case issues it deals with. Consumers in their current lifestyle have minimal time for natural pain recovery. Practitioners often face incidences where patients, in order to get back to their normal routines as quickly as possible, describe their ‘pain’ to be ‘extremely severe’. Seldom do they realize, the after effects of targeted intravenous ibuprofen. Consumers lack awareness of the action strategy of intravenous administration and might later end with huge health regrets. Moreover, the easy availability of both the drug and injecting equipment without any prescription makes it harder to keep a track of individual dosages in a patient. It is therefore, crucial on the part of pharmaceutical vendors to observe each footfall and relate possibilities of mishaps at their level.
As in favor of intravenous ibuprofen market, the uncomfortable living routines of modern population, added to the established market the drug has created for itself over the years, net overall sales are not going to dip anytime soon. With proper awareness campaigns from government organizations and private healthcare agencies it is possible to tie down the numbers of overdose fatalities or reduce detrimental functions due to prolonged usage. Stipulated risks associated with accidental stick injury and spreading of contagious diseases, caused by incorrect injection techniques, add to the growth restraints. Bright part – smart syringes. With the introduction of smart disposable injecting devices at consumer platforms, critics get to rest their arguments in the current decade. More importantly, health conscious consumer segment avail cost-effective solutions for easy pain management. Recent ventures by developers of drug delivery devices, into variating the route induction of this popular anti-inflammatory drug should alert the manufacturers and vendors of the segment. Business stakeholders need to look out for strategic methods to maintain their market share in the industry.
Certain issues remain to be dealt regarding IV ibuprofen medication when it comes to the auxiliary effects on bodily functions. Concerns have been raised against its usage among pediatric and geriatric class, pregnant & breastfeeding women, and patients on simultaneous medication or with a critical medical history. A compulsory black box marking enforced by the FDA, in due while, is expected to help increase consumer awareness against harmful effects of ibuprofen overdose and its prolonged usage. Pharmaceutical companies have been investing a huge amount of time and infrastructure, dedicated to their research and development facilities. Mostly, the researches aim towards perfecting the right intravenous concentration, rate of injection, duration of administrated sessions, and exact timing of IV ibuprofen infusion for better patient outcomes.
Analytical experts at Allied Market Research evaluated IV ibuprofen market size to be $3.6 million in 2015. A quantitative study of financial ratios obtained as inputs from the industry has been compiled in their recently published report “World Intravenous (IV) Ibuprofen Market - Opportunities and Forecasts, 2015 – 2022.” According to the report, industry shall be worth $14.2 million by 2022, registering a CAGR of 20% during the forecast period. It takes into account the growth drivers and restraints, emerging demand trends, and advanced delivery techniques that shapes future markets. Outlined are the opportunity segments that prevail in this competitive scenario, for the benefit of business stakeholders and investors.
Brows all latest report of medical devices at: https://www.alliedmarketresearch.com/life-sciences/medical-devices-market-report
Akhilesh Prabhugaonkar
Author's Bio- Akhilesh Prabhugaonkar holds a bachelor’s degree in Electronics Engineering from the reputed Vishwakarma Institute of Technology. He has a special interest in the fields of forensics, world history, international relations and foreign policy, sports, agriculture, astronomy, security, and oceanography. An ardent bibliophile and melophile, Akhilesh loves to write on topics of his interest and various other societal issues. This love for writing made him enter the professional world of content writing and pursue his career in this direction.
How are Submarine Cables Transforming Global Connectivity with Enhanced User Experience?
How Integrating Advanced AC Electric Motors Does Optimize Equipment Potential?
How Industrial Fasteners Are Adapting to New Engineering Needs
How Embedded Computing is Transforming AI, Security, and Automation
EV Charging Software: The Backbone of Charging Infrastructure
Automotive Power Window Motors: Powering the Future of Modern Vehicles
Electrical Park Brakes: An Innovative Solution to Boost Vehicle Safety
AI in Speech-to-Text Programming: A Promising Voice Recognition Solution